Our Network Saphnelo data show patients more likely to achieve and sustain remission in systemic lupus erythematosus compared to standard therapy alone Tags: #Rheumatology #Clinical research #AstraZeneca AstraZeneca presents new evidence from TULIP Phase III programme as part of 18 total abstracts across its Immunology portfolio at ACR 2023.
